After the first sale of the new-gen microscope, the Ikoniscope20, to one of the biggest genetic laboratories in Italy, we confirm our Buy rating for the shares of Ikonisys and our three-stage discounted cash flow entity model (primary valuation method) share price target of EUR 7.70.
Ikonisys announced the sale and installation of the Ikoniscope20 at Toma Advanced Biomedical Assays Spa (“TomaLab”) in Busto Arsizio near Milan. TomaLab has been successfully validating the Ikoniscope20 for routine FISH testing in oncology, using several applications that span from lung cancer (oncoFISH ALK) to bladder cancer (oncoFISH bladder).
With revenues of more than EUR 20m and approximately 100 employees, TomaLab is one of the biggest accredited medical analysis laboratories in Italy, offering a full range of genetic diagnostic services in oncology, reproduction, ophthalmology, cardiology, and forensic genetics. The company operates specialised departments for clinical biochemistry and toxicology, microbiology and virology, pathological anatomy, cytogenetics and medical genetics.
According to Ikonisys, TomaLab will continue to collaborate on the development of novel applications for tests that will be of particular interest in the field of cancer diagnostics, especially regarding the Ikoniscope’s ability to perform both FISH- and antibody-based tests. In addition, due to the particularly high level of qualification, TomaLab will act as a reference laboratory for Ikonisys. Potential clients of Ikonisys will be informed by TomaLab about the advantages and special characteristics of the Ikoniskope20. In our view this could significantly shorten the sales cycle for Ikonisys in the future.
Founded in 2010, Sphene Capital is a German based pure-play research house offering state-of-the-art research and evaluation services to European small- and mid-caps by avoiding typical conflict of interests of traditional investment banks.
As a general rule, analysts of Sphene Capital strive to understand companies better than any other analyst or investor before publishing their initiation reports. Therefore, the comprehensive initiation research reports comprise of 50-80 pages, including an extensive analysis of the value chain of the IPO candidate, its unique selling proposition, an elaborate analysis of suppliers and clients, a thorough SWOT analysis, a commercial due diligence (i. e. market and competitive analysis), an integrated financial forecast model and a profound company valuation (both DCF methodology and peer group multiples). Before publication, each of Sphene Capital’s research report will be double-checked by a fellow research colleague (“Four-eyes-principle”), ensuring highest quality and avoiding careless mistakes.
After initiation of research coverage, Sphene Capital publishes regular updates of 12-30 pages following relevant news flow from the issuer or major peers, f. ex. after acquisitions or after publication of quarterly results.
Due to Sphene Capital’s extensive experience in equity and bond research, the team has established longstanding contacts to all relevant market players, i. e. institutional investors, family offices and high net-worth individuals as well as journalists. To each of these groups, Sphene Capital’s research analysts have regular contacts during analyst and management roadshows or via daily phone calls. Finally, analysts publish articles in selected stock markets magazines and websites in which the analysts help issuers to improve their popularity on the German capital markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.